Inventiva announces the decision by the investigator to reduce the number of patients in the ongoing Phase II trial evaluating lanifibranor in type 2 diabetes patients (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD)
We value your privacy
We use cookies to improve your browsing experience, analyse traffic and, with your consent, personalise content. You can accept, reject or customise your choices.
Cookie preferences
Enable or disable cookie categories. Strictly necessary cookies are always active.
Strictly necessary
Essential for the website to function (navigation, security, session). They cannot be disabled.
Functional
Improve usability: remembering language, region and your preferences.
Statistics
Help us understand how the site is used (page views, audience) to optimise it.
Marketing
Allow relevant advertising to be shown and campaigns to be measured.
